255 related articles for article (PubMed ID: 30016392)
21. Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors.
Mita M; Gordon M; Rosen L; Kapoor N; Choy G; Redkar S; Taverna P; Oganesian A; Sahai A; Azab M; Bristow R; Tolcher AW
Cancer Chemother Pharmacol; 2014 Jul; 74(1):195-204. PubMed ID: 24849582
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.
Belani CP; Dakhil S; Waterhouse DM; Desch CE; Rooney DK; Clark RH; Monberg MJ; Ye Z; Obasaju CK
Ann Oncol; 2007 Jan; 18(1):110-115. PubMed ID: 17043094
[TBL] [Abstract][Full Text] [Related]
23. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
[TBL] [Abstract][Full Text] [Related]
24. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA
Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791
[TBL] [Abstract][Full Text] [Related]
25. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
26. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
Padda SK; Reckamp KL; Koczywas M; Neal JW; Kawashima J; Kong S; Huang DB; Kowalski M; Wakelee HA
Cancer Chemother Pharmacol; 2022 Jan; 89(1):105-115. PubMed ID: 34773474
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of bi-weekly paclitaxel and gemcitabine as second-line therapy for patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Koizumi T; Yoshiike F; Inou H; Hatayama O; Sasabayashi M; Tsushima K; Yamamoto H; Hayasaka M; Kubo K
Med Oncol; 2004; 21(2):133-7. PubMed ID: 15299185
[TBL] [Abstract][Full Text] [Related]
28. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.
Borghaei H; Langer CJ; Millenson M; Ruth KJ; Litwin S; Tuttle H; Seldomridge JS; Rovito M; Mintzer D; Cohen R; Treat J
J Thorac Oncol; 2008 Nov; 3(11):1286-92. PubMed ID: 18978564
[TBL] [Abstract][Full Text] [Related]
30. Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
Backes FJ; Wei L; Chen M; Hill K; Dzwigalski K; Poi M; Phelps M; Salani R; Copeland LJ; Fowler JM; Cohn DE; Bixel K; Cosgrove C; Hays J; O'Malley D
Gynecol Oncol; 2021 Sep; 162(3):619-625. PubMed ID: 34272090
[TBL] [Abstract][Full Text] [Related]
31. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer.
Lorusso V; Crucitta E; Panza N; Silvestris N; Guida M; Carpagnano F; Mancarella S; Sambiasi D; De Lena M
Ann Oncol; 2002 Dec; 13(12):1862-7. PubMed ID: 12453853
[TBL] [Abstract][Full Text] [Related]
33. Phase I/II trial of paclitaxel and vinorelbine in advanced non-small cell lung cancer.
Grunberg SM; Dugan MC; Greenblatt MS; Ospina DJ; Valentine JW
Cancer Invest; 2005; 23(5):392-8. PubMed ID: 16193638
[TBL] [Abstract][Full Text] [Related]
34. Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer.
Natale RB
Semin Oncol; 1996 Oct; 23(5 Suppl 12):2-6. PubMed ID: 8941402
[TBL] [Abstract][Full Text] [Related]
35. Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.
Feliu J; Martin G; Lizón J; Chacón JI; Dorta J; de Castro J; Rodríguez A; Sánchez Heras B; Torrego JC; Espinosa E; González Barón M;
Ann Oncol; 2001 Oct; 12(10):1369-74. PubMed ID: 11762806
[TBL] [Abstract][Full Text] [Related]
36. The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: a phase I-II study of paclitaxel, cisplatin, and vinorelbine.
Lokich JJ; Anderson N; Bern M; Coco F; Dow E
Cancer; 1999 Jan; 85(2):499-503. PubMed ID: 10023721
[TBL] [Abstract][Full Text] [Related]
37. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
[TBL] [Abstract][Full Text] [Related]
39. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Falchook G; Coleman RL; Roszak A; Behbakht K; Matulonis U; Ray-Coquard I; Sawrycki P; Duska LR; Tew W; Ghamande S; Lesoin A; Schwartz PE; Buscema J; Fabbro M; Lortholary A; Goff B; Kurzrock R; Martin LP; Gray HJ; Fu S; Sheldon-Waniga E; Lin HM; Venkatakrishnan K; Zhou X; Leonard EJ; Schilder RJ
JAMA Oncol; 2019 Jan; 5(1):e183773. PubMed ID: 30347019
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Font A; Sanchez JM; Rosell R; Taron M; Martinez E; Guillot M; Manzano JL; Margeli M; Barnadas A; Abad A
Lung Cancer; 2002 Aug; 37(2):213-8. PubMed ID: 12140145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]